.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The EOLIA trial compared early venovenous extracorporeal membrane oxygenation with conventional management in adults with very severe ARDS. Patients randomised to ECMO were transferred to experienced centres and received extracorporeal support when predefined criteria were met, while the control group received modern conventional therapy including lung-protective ventilation and, in most patients, prone positioning. The trial did not show a statistically significant reduction in 60-day mortality with ECMO. Nevertheless, crossover from the control group to ECMO occurred, and the mortality difference favoured ECMO, contributing to continued debate about its use as rescue therapy. The clinical lesson is that ECMO should not be viewed as a simple “next step” after conventional ventilation fails. Outcomes depend heavily on timing, patient selection, experienced teams and the quality of pre-ECMO management. EOLIA also underscores the importance of applying lung-protective ventilation and prone positioning before declaring conventional therapy unsuccessful. In selected patients with refractory, potentially reversible respiratory failure, ECMO remains a valuable rescue option, but the evidence does not support routine early use for every patient with severe ARDS. The trial therefore supports a centre-expertise and phenotype-based approach to ECMO referral rather than a single universal threshold.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The EOLIA trial compared early venovenous extracorporeal membrane oxygenation with conventional management in adults with very severe ARDS. Patients randomised to ECMO were transferred to experienced centres and received extracorporeal support when predefined criteria were met, while the control group received modern conventional therapy including lung-protective ventilation and, in most patients, prone positioning. The trial did not show a statistically significant reduction in 60-day mortality with ECMO. Nevertheless, crossover from the control group to ECMO occurred, and the mortality difference favoured ECMO, contributing to continued debate about its use as rescue therapy. The clinical lesson is that ECMO should not be viewed as a simple “next step” after conventional ventilation fails. Outcomes depend heavily on timing, patient selection, experienced teams and the quality of pre-ECMO management. EOLIA also underscores the importance of applying lung-protective ventilation and prone positioning before declaring conventional therapy unsuccessful. In selected patients with refractory, potentially reversible respiratory failure, ECMO remains a valuable rescue option, but the evidence does not support routine early use for every patient with severe ARDS. The trial therefore supports a centre-expertise and phenotype-based approach to ECMO referral rather than a single universal threshold.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
Yesterday
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
2 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
2 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
